000			02248 a2200577 4500
005			20250515052015.0
264		0	_c20070308
008			200703s 0 0 eng d
022			_a1744-8328
024	7		_a10.1586/14737140.6.12.1761 _2doi
040			_aNLM _beng _cNLM
100	1		_aPouessel, Damien
245	0	0	_aTargeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel. _h[electronic resource]
260			_bExpert review of anticancer therapy _cDec 2006
300			_a1761-7 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAngiogenesis Inhibitors _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aBenzenesulfonates _xtherapeutic use
650	0	4	_aBevacizumab
650	0	4	_aCarcinoma, Renal Cell _xdrug therapy
650	0	4	_aChemotherapy, Adjuvant
650	0	4	_aDrug Delivery Systems
650	0	4	_aDrug Therapy, Combination
650	0	4	_aForecasting
650	0	4	_aHumans
650	0	4	_aImmunologic Factors _xtherapeutic use
650	0	4	_aImmunotherapy
650	0	4	_aIndoles _xtherapeutic use
650	0	4	_aInterferon-alpha _xadministration & dosage
650	0	4	_aInterleukin-2 _xadministration & dosage
650	0	4	_aKidney Neoplasms _xtherapy
650	0	4	_aNeoplasm Proteins _xantagonists & inhibitors
650	0	4	_aNiacinamide _xanalogs & derivatives
650	0	4	_aPhenylurea Compounds
650	0	4	_aProtein Kinase Inhibitors _xtherapeutic use
650	0	4	_aProtein Kinases _xdrug effects
650	0	4	_aPyridines _xtherapeutic use
650	0	4	_aPyrroles _xtherapeutic use
650	0	4	_aReceptors, Vascular Endothelial Growth Factor _xantagonists & inhibitors
650	0	4	_aSirolimus _xanalogs & derivatives
650	0	4	_aSorafenib
650	0	4	_aSunitinib
650	0	4	_aTOR Serine-Threonine Kinases
700	1		_aCuline, Stéphane
773	0		_tExpert review of anticancer therapy _gvol. 6 _gno. 12 _gp. 1761-7
856	4	0	_uhttps://doi.org/10.1586/14737140.6.12.1761 _zAvailable from publisher's website
999			_c16749189 _d16749189